Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Metastatic pancreatic cancer patients ineligible for surgery have seen limited survival benefits from current signal-targeted therapies.
• Existing treatments often combine targeted therapies with gemcitabine, with modest success.
• Pancreatic tumors exhibit significant heterogeneity, complicating the identification of specific oncogene dependencies beyond Kras.

Purpose of the Study:

• To review the current clinical trial landscape for targeted therapies in pancreatic cancer.
• To highlight recent proteomic data to identify oncogenic signaling dependencies and resistance mechanisms.
• To explore the role of phosphatidylinositol-3-kinase (PI3K) signaling in pancreatic cancer and its potential as a therapeutic target.

Main Methods:

• Review of existing clinical trial data for targeted therapies in pancreatic cancer.
• Analysis of recent large-scale transcriptomic and genomic data.
• Exploration of proteomic data to identify targetable alterations and signaling dependencies.

Main Results:

• Transcriptomic and genomic analyses reveal heterogeneity but struggle to pinpoint specific oncogene dependencies beyond Kras.
• Proteomics presents a viable strategy for classifying signal dependencies and identifying targetable alterations, despite data scarcity.
• Phosphatidylinositol-3-kinase (PI3K) signaling is a key pro-tumoral pathway downstream of Kras in pancreatic cancer.

Conclusions:

• Proteomic insights are crucial for understanding pancreatic cancer's intrinsic resistance to signal-targeted therapies.
• Further proteomic studies, particularly on PI3K signaling, could enhance the efficacy of targeted treatments.
• Identifying and targeting specific oncogenic dependencies and stromal normalization are key future therapeutic strategies.